Rehan Jamil Haidry

Rehan Jamil Haidry


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in Endoscopy
Verified
Journal Article
Closed access
PDF file
APApostolis Papaefthymiou
Apostolis Papaefthymiou
PGParaskevas Gkolfakis
Paraskevas Gkolfakis
KBKirill Basiliya
Kirill Basiliya
DRDaryl Ramai
Daryl Ramai
Georgios TziatziosGeorgios Tziatzios
Georgios Tziatzios
RHRehan Jamil Haidry
Rehan Jamil Haidry
Background Esophageal stenting is an important intervention for managing malignant and benign dysphagia, with stent migration representing a common drawback. This systematic review with meta-analysis aimed to assess the benefit of stent fixation over nonfixation. Methods A systematic search was performed in MEDLINE, Cochrane, Scopus, and ClinicalTrials.gov databases until January 2023 for comparative studies evaluating the migration rates of esophageal stents with versus without (control) fixation. The primary outcome was migration rate. Secondary outcomes included adverse event rate. A subgroup analysis stratified the results based on different fixation techniques: suturing, over-the-scope (OTS) clipping, and through-the-scope (TTS) clipping. Meta-analysis was based on a random effects model and the results were reported as odds ratios (ORs) with 95 %CIs. Results 10 studies (1014 patients) were included. The rate of stent migration was significantly lower after fixation (OR 0.20, 95 %CI 0.11–0.37; I2 = 59 %, P = 0.01). The adverse event rate was similar between fixation and control groups (OR 0.65, 95 %CI 0.28–1.52; I2 = 55 %, P = 0.06). In the subgroup analysis, all fixation techniques remained superior to nonfixation of stents (suturing OR 0.23, 95 %CI 0.10–0.53; OTS clips OR 0.31, 95 %CI 0.17–0.58; TTS clips OR 0.10, 95 %CI 0.03–0.38); however, only the OTS and TTS clip groups achieved nonsignificant heterogeneity (I2 = 0 %, P = 0.67 and P = 0.73, respectively). No difference between techniques was recorded for migration rates. Conclusion Esophageal stent fixation was associated with significantly lower migration rates compared with nonfixation of stents, regardless of fixation technique and stenting indication.

4 May 2024 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Open access
APApostolis Papaefthymiou
Apostolis Papaefthymiou
BNBenjamin Charles Norton
Benjamin Charles Norton
ATAndrea Telese
Andrea Telese
CMCharlie Murray
Charlie Murray
AMAlberto Murino
Alberto Murino
RHRehan Jamil Haidry
Rehan Jamil Haidry
Gastrointestinal luminal defects, including perforations, leaks and fistulae, pose persistent obstacles in endoscopic therapeutic interventions. A variety of endoscopic approaches have been proposed, with through-the-scope clipping (TTSC), over-the-scope clipping (OTSC) and suturing representing the main techniques of tissue apposition. However, the heterogeneity in defect morphology, the technical particularities of different locations in the gastrointestinal (GI) tract and the impact of various parameters on the final outcome, do not allow distinct conclusions and recommendations on the optimal approaches for defect closure, and, thus, current practice is based on endoscopists experience and local availability of devices. This review aims to collect the existing evidence on tissue apposition devices, in order to outline the role of every device on specific indications.

23 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
APApostolis Papaefthymiou
Apostolis Papaefthymiou
BNBenjamin Charles Norton
Benjamin Charles Norton
ATAndrea Telese
Andrea Telese
DRDaryl Ramai
Daryl Ramai
AMAlberto Murino
Alberto Murino
RHRehan Jamil Haidry
Rehan Jamil Haidry
Background: The mainstay approach in endoscopic eradication therapy (EET) for dysplastic Barrett’s esophagus (BE) includes the endoscopic resection of visible lesions, accompanied by ablation of the residual metaplastic epithelium. Cryoablation therapy is one such emerging ablation technique in this field. This systematic review with a meta-analysis aims to accumulate pooled data on cryoablation performance in the treatment of patients with BE and to compare this technique to the standard of care radiofrequency ablation (RFA). Methods: The MEDLINE, Cochrane, and Scopus databases were searched until June 2024 for studies evaluating BE management using cryoablation for cumulative results. The primary outcome was the complete eradication of dysplasia (CED) and intestinal metaplasia (CEIM) in BE compared to RFA, while secondary outcomes included the respective pooled rates using cryoablation, recurrence, and adverse events, with a separate analysis for strictures. The meta-analyses were based on a random-effects model, and the results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analyses by type of cryoablation were also performed. Results: Twenty-three studies (1604 patients) were finally included, four of which were comparative. CED and CEIM did not differ significantly between cryoablation and RFA [OR= 0.95 (95%CI: 0.50–1.81) and OR = 0.57 (95%CI: 0.20–1.63), respectively)]. The pooled rates of CED, CEIM, and recurrence after cryoablation were 84.2% (95%CI: 79.1–89.3), 64.1% (95%CI: 49.2–79.0), and 8.3% (95%CI: 4.7–11.9), accompanied by high rates of heterogeneity. Adverse events were noted in 14.5% (95%CI: 9.9–19.2) of cases, and 6.5% (95%CI: 4.1–9.0) developed strictures. In the subgroup analysis, the cryoballoon achieved a reduction in heterogeneity in CED, adverse events, and stricture formation, whereas spray catheters provided homogenous results in terms of recurrence. Conclusions: Cryoablation provides equal outcomes compared to RFA in the treatment of patients with BE, with the cryoballoon achieving relatively homogenous rates of CED and adverse events.

9 January 2024 in Endoscopy
Verified
Journal Article
Open access
PDF file
APApostolis Papaefthymiou
Apostolis Papaefthymiou
BNBenjamin Charles Norton
Benjamin Charles Norton
PHPablo Becerra Hoebel
Pablo Becerra Hoebel
LGLeonardo Rodriguez Grunert
Leonardo Rodriguez Grunert
RHRehan Jamil Haidry
Rehan Jamil Haidry
Duodenal mucosal ablation is an emerging endoscopic technique for the management of metabolic diseases, providing promising results for the control of type 2 diabetes [1] [2]. The continuous advancement of endoscopic devices aims to optimize procedural efficacy, operability, and scalability [3]. A novel through-the-scope ablation device, the circumferential radiofrequency vapor ablation system (Aqua Medical, Pleasanton, California, USA), is currently under evaluation in a first-in-human clinical trial (NCT05887635). This device consists of a 10.5-Fr through-the-scope catheter-based system with an ablation segment 2.5 cm in length ([Fig. 1]). Energy is delivered to the duodenal mucosa in the form of heated water vapor generated within the catheter tip using radiofrequency. Positioning discs attached to the tip direct the distribution of vapor to the targeted duodenal tissue and allow circumferential mucosal ablation. We present the case of a patient with poorly controlled type 2 diabetes who was eligible for recruitment and underwent the procedure under general anesthesia, using a double-channel endoscope ([Video 1]). The patient was on metformin and had a fasting blood glucose level of 127 mg/dL and HbA1c of 8.3%. The duodenal mucosa was initially reviewed and washed with 2% N-acetylcysteine solution, and the fluid was suctioned. The ampulla was identified, representing the landmark of the proximal end of the area to be treated, and marked by deploying a clip on the contralateral wall. The first ablation was delivered immediately distal to the clip, and subsequent ablations were performed in a proximal-to-distal direction with minimal overlap. After the first series of ablations, the mucosa was reviewed, and a second series of ablations was carried out over the initial treatment zone ([Fig. 2]). Finally, the entire ablated segment was reviewed for complications and remaining nonablated segments. The patient was monitored for 24 hours post-procedure and remained asymptomatic. No adverse events were recorded prior to discharge. Follow-up after 1 month confirmed the absence of adverse events and a reduction in fasting blood glucose (118 mg/dl) and HbA1c (6.5%) levels. This new circumferential radiofrequency vapor ablation system for duodenal mucosal ablation presents a promising intervention for type 2 diabetes. Results from the first-in-human STEAM T-2DM trial will provide insights into the overall safety and efficacy of this technique. Endoscopy_UCTN_Code_TTT_1AO_2AN Article published online: 03 July 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

15 February 2024 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
BNBenjamin Charles Norton
Benjamin Charles Norton
APApostolis Papaefthymiou
Apostolis Papaefthymiou
ATAndrea Telese
Andrea Telese
RMRitwika Mallik
Ritwika Mallik
AMAlberto Murino
Alberto Murino
RHRehan Jamil Haidry
Rehan Jamil Haidry
Type 2 diabetes (T2D) is one of the most significant and fast-growing health challenges of the 21st century. Despite the variety of available glucose-lowering agents, many patients do not attain or maintain adequate glycaemic control. Bariatric surgery demonstrates a profound anti-diabetic effect, which is almost immediate and weight-loss independent. The significant improvement in diabetes after bariatric surgery together with the endoscopic accessibility of the duodenum has led to the development of new metabolic endoscopic procedures that capitalise on the importance of the proximal small bowel in glycaemic control. Clinical trials have shown a clear efficacy signal, and now, several devices are undergoing evaluation as primary T2D treatments. Establishing where these procedures fit into the treatment algorithms for T2D and how they can be combined with modern pharmacotherapies is needed in a rapidly changing landscape. Ultimately, through metabolic endoscopy, gastroenterologists are on the cusp of providing safe and effective treatments for the multidisciplinary management of T2D.

13 September 2023 in Life
Verified
Journal Article
Open access
PDF file
BNBenjamin Charles Norton
Benjamin Charles Norton
ATAndrea Telese
Andrea Telese
APApostolis Papaefthymiou
Apostolis Papaefthymiou
NANasar Aslam
Nasar Aslam
JMJanine Makaronidis
Janine Makaronidis
RHRehan Jamil Haidry
Rehan Jamil Haidry
We are currently in a worldwide obesity pandemic, which is one of the most significant health problems of the 21st century. As the prevalence of obesity continues to rise, new and innovate treatments are becoming available. Metabolic and bariatric endoscopic procedures are exciting new areas of gastroenterology that have been developed as a direct response to the obesity crisis. These novel interventions offer a potentially reversible, less invasive, safer, and more cost-effective method of tackling obesity compared to traditional bariatric surgery. Minimally invasive endoscopic treatments are not entirely novel, but as technology has rapidly improved, many of the procedures have been proven to be extremely effective for weight loss and metabolic health, based on high-quality clinical trial data. This mini-review examines the existing evidence for the most prominent metabolic and bariatric procedures, followed by a discussion on the future trajectory of this emerging subspecialty.